New hope for diabetic eye disease: experimental drug SNP318 enters Mid-Stage trial
NCT ID NCT07199777
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called SNP318 in 60 people with diabetic macular edema, a condition that causes vision loss due to swelling in the retina. Participants will receive either the drug or a placebo, and researchers will monitor safety, eye thickness, and vision changes over time. The goal is to see if SNP318 can help control the disease and improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection preserve vision in south asians with diabetes?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?
- Eye injection aims to tame leading causes of blindness
- New eye drug aims to restore vision in Diabetes-Related swelling